News and Announcements
Credi Pty Ltd’s CEO set to join FinTech Australia’s board
- Published July 10, 2018 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
KEY TAKEAWAYS:
- Credi CEO, Tim Dean to join FinTech Australia board.
- Fintech Australia is the fintech industry’s national body, providing everything from networking to advocacy.
- Tim Dean aims to help WA-base fintech companies overcome geographical problems.
Credi’s CEO and founder, Tim Dean, will join the board of FinTech Australia, the national body for the financial technology industry in Australia providing everything from networking to advocacy. The position will allow Tim to face the geographical challenges WA-based Fintech companies face. WA fintech companies make up 9% of the industry nationally. Tim has suggested that for WA-based companies to become key players, is to enter Australian-Asian based relationships.
Tim brings the knowledge of working in a Fintech company, Credi, which has people using the platform in 27 countries and moving into their revenue phase. He believes that FinTech Australia can help form relationships at federal and state level governments to get access to national events. It will allow for WA-based companies to network and gain access to like-minded companies. He explains, “As a fintech business owner, it’s always important to have access to any advocacy groups that are in your space…I suppose I work on the basis that if you are in something, you should also be prepared to contribute to both your good and everyone else’s as well.”
About Credi Pty Ltd
If you’ve ever loaned your children money you are officially a branch manager of “The Bank of Mum and Dad”. You are also a part of one of fast growing sectors of the Australian economy. Credi.com was born out of the pressing need to document loans between family members, friends and businesses. It removes the stress, the embarrassment and the risk of legal action, formalising a loan within minutes and without a scrap of costly, time-consuming paperwork.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
